Biolinerx

APHEXDA

Manufacturer:

Biolinerx

Aphexda HCPCS:

J2277

HCPCS Code Descriptor:

Injection, motixafortide, 0.25 mg

Category:

J Code

Aphexda NDCs:

82737-0073-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Not Found

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Aphexda:

APHEXDA is aligned to the J Code: J2277. APHEXDA is an Oncology drug produced by Biolinerx and administered via the Subcutaneous route of administration.

ACCESS PRICING AND MORE BY REGISTERING

J2277 Added Date:

4/1/24

J2277 Effective Date:

4/1/24

J2277 Deactive Date:

HCPCS Active

We have not yet identified a manufacturer source of billing and coding information for Aphexda
Aphexda patient assistance information can be found through Biolinerx at the URL: https://www.aphexda.com/patient-support-and-resources#biolinerx-connect
APHEXDA prescribing information can be found at the link below:
Our team has not yet identified a source of side effect information for APHEXDA